New hope for stubborn low platelets after transplant?
NCT ID NCT07535645
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the drug baricitinib in 28 adults who have dangerously low platelet counts after a stem cell transplant and did not improve with standard treatments. The goal is to see if baricitinib can safely raise platelet levels enough to reduce the need for transfusions. The study is in early phases (1b/2) and is not yet recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Life-Saving transplant leave hidden scars on a Child's mind?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Could a simple drug infusion stop a dangerous virus after stem cell transplants?
- Study to reveal if younger donors boost transplant success
- Can donor t cells beat a tough virus after transplant? new trial aims to find out.
- Ancient heat therapy tested for Life-Threatening transplant complication